The outcomes of patients with metastatic urothelial carcinoma (mUC) and non-muscle invasive urothelial carcinoma (NMIBC) following disease progression on standard-of-care therapy remain poor. Approximately 20% and 30% of such cancers, respectively, harbour FGFR alterations. Now, the results of three comparative trials in various disease settings provide insight into the role of the FGFR inhibitor erdafitinib in urothelial carcinoma.